You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Impact of X-Linked Hypophosphatemia on Muscle Symptoms: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jason Zhu and Version 1 by Cecilia Romagnoli.

X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and deficiency of renal tubular phosphate transport in humans. XLH is caused by the inactivation of mutations within the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene and follows an X-dominant transmission. It has an estimated frequency of 1 case per 20,000, and over 300 distinct pathogenic variations have been reported that result in an excess of fibroblast growth factor 23 (FGF23) in the serum. Increased levels of FGF23 lead to renal phosphate loss, decreased serum 1,25-dihydroxyvitamin D, and increased metabolism of 1,25-dihydoxyvitamin D, resulting in hypophosphatemia. Major clinical manifestations include rickets, bone deformities, and growth retardation that develop during childhood, and osteomalacia-related fractures or pseudo-fractures, degenerative osteoarthritis, enthesopathy, dental anomalies, and hearing loss during adulthood, which could affect quality of life. In addition, fatigue is also a main symptom in patients with XLH, who experience decreased motion, muscle weakness, and pain, contributing to altered quality of life. The clinical and biomedical characteristics of XLH are extensively defined in bone tissue since skeletal deformations and mineralization defects are the most evident effects of a high FGF23 and low serum phosphate levels. However, despite the muscular symptoms that XLH causes, very few reports are available about the effects of FGF23 and phosphate in muscle tissue. Given the close relationship between bones and skeletal muscles, studying the effects of FGF23 and phosphate on muscle could provide additional opportunities to understand the interactions between these two important compartments of the body. By describing current literature about XLH and skeletal muscle dysfunctions, the purpose of this review is to highlight future areas of research that could contribute to a better understanding of XLH muscular disability and its management.

  • X-linked hypophosphatemia
  • FGF23
  • skeletal muscle
  • muscle weakness
  • skeletal muscle dysfunction
Please wait, diff process is still running!

References

  1. Dahir, K.; Roberts, M.S.; Krolczyk, S.; Simmons, J.H. X-Linked Hypophosphatemia: A New Era in Management. J. Endocr. Soc. 2020, 4, Bvaa151.
  2. Haffner, D.; Emma, F.; Eastwood, D.M.; Duplan, M.B.; Bacchetta, J.; Schnabel, D.; Wicart, P.; Bockenhauer, D.; Santos, F.; Levtchenko, E.; et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 2019, 15, 435–455.
  3. Rothenbuhler, A.; Schnabel, D.; Högler, W.; Linglart, A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism 2020, 103S, 153892.
  4. Barros, N.M.T.; Hoac, B.; Neves, R.L.; Addison, W.N.; Assis, D.M.; Murshed, M.; Carmona, A.K.; McKee, M.D. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J. Bone Miner. Res. 2013, 28, 688–699.
  5. Liu, S.; Guo, R.; Simpson, L.G.; Xiao, Z.-S.; Burnham, C.E.; Quarles, L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 2003, 278, 37419–37426.
  6. Kinoshita, Y.; Fukumoto, S. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocr. Rev. 2018, 39, 274–291.
  7. Makras, P.; Hamdy, N.A.T.; Kant, S.G.; Papapoulos, S.E. Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. J. Clin. Endocrinol. Metab. 2008, 93, 1386–1389.
  8. Carpenter, T.O.; Imel, E.A.; Holm, I.A.; Jan de Beur, S.M.; Insogna, K.L. A clinician’s guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26, 1381–1388.
  9. Beck-Nielsen, S.S.; Brusgaard, K.; Rasmussen, L.M.; Brixen, K.; Brock-Jacobsen, B.; Poulsen, M.R.; Vestergaard, P.; Ralston, S.H.; Albagha, O.M.E.; Poulsen, S.; et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif. Tissue Int. 2010, 87, 108–119.
  10. Gaucher, C.; Walrant-Debray, O.; Nguyen, T.-M.; Esterle, L.; Garabédian, M.; Jehan, F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum. Genet. 2009, 125, 401–411.
  11. Popowska, E.; Pronicka, E.; Sułek, A.; Jurkiewicz, D.; Rowe, P.; Rowinska, E.; Krajewska-Walasek, M. X-linked hypophosphatemia in Polish patients. 1. Mutations in the PHEX gene. J. Appl. Genet. 2000, 41, 293–302.
  12. Imel, E.A.; DiMeglio, L.A.; Hui, S.L.; Carpenter, T.O.; Econs, M.J. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J. Clin. Endocrinol. Metab. 2010, 95, 1846–1850.
  13. Morey, M.; Castro-Feijóo, L.; Barreiro, J.; Cabanas, P.; Pombo, M.; Gil, M.; Bernabeu, I.; Díaz-Grande, J.M.; Rey-Cordo, L.; Ariceta, G.; et al. Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med. Genet. 2011, 12, 116.
  14. Shore, R.M.; Chesney, R.W. Rickets: Part I. Pediatr. Radiol. 2013, 43, 140–151.
  15. Linglart, A.; Biosse-Duplan, M.; Briot, K.; Chaussain, C.; Esterle, L.; Guillaume-Czitrom, S.; Kamenicky, P.; Nevoux, J.; Prié, D.; Rothenbuhler, A.; et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect. 2014, 3, R13–R30.
  16. Mäkitie, O.; Doria, A.; Kooh, S.W.; Cole, W.G.; Daneman, A.; Sochett, E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2003, 88, 3591–3597.
  17. Rasmussen, H.; Pechet, M.; Anast, C.; Mazur, A.; Gertner, J.; Broadus, A.E. Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3. J. Pediatr. 1981, 99, 16–25.
  18. Chesher, D.; Oddy, M.; Darbar, U.; Sayal, P.; Casey, A.; Ryan, A.; Sechi, A.; Simister, C.; Waters, A.; Wedatilake, Y.; et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J. Inherit. Metab. Dis. 2018, 41, 865–876.
  19. Hardy, D.C.; Murphy, W.A.; Siegel, B.A.; Reid, I.R.; Whyte, M.P. X-linked hypophosphatemia in adults: Prevalence of skeletal radiographic and scintigraphic features. Radiology 1989, 171, 403–414.
  20. Che, H.; Roux, C.; Etcheto, A.; Rothenbuhler, A.; Kamenicky, P.; Linglart, A.; Briot, K. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur. J. Endocrinol. 2016, 174, 325–333.
  21. Raeder, H.; Shaw, N.; Netelenbos, C.; Bjerknes, R. A case of X-linked hypophosphatemic rickets: Complications and the therapeutic use of cinacalcet. Eur. J. Endocrinol. 2008, 159 (Suppl. 1), S101–S105.
  22. Insogna, K.L.; Briot, K.; Imel, E.A.; Kamenický, P.; Ruppe, M.D.; Portale, A.A.; Weber, T.; Pitukcheewanont, P.; Cheong, H.I.; Jan de Beur, S.; et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J. Bone Miner. Res. 2018, 33, 1383–1393.
  23. Brandi, M.L.; Jan de Beur, S.; Briot, K.; Carpenter, T.; Cheong, H.I.; Cohen-Solal, M.; Crowley, R.K.; Eastell, R.; Imanishi, Y.; Imel, E.A.; et al. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif. Tissue Int. 2022, 111, 409–418.
  24. Briot, K.; Portale, A.A.; Brandi, M.L.; Carpenter, T.O.; Cheong, H.I.; Cohen-Solal, M.; Crowley, R.K.; Eastell, R.; Imanishi, Y.; Ing, S.; et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 2021, 7, e001714.
  25. Imel, E.A.; Glorieux, F.H.; Whyte, M.P.; Munns, C.F.; Ward, L.M.; Nilsson, O.; Simmons, J.H.; Padidela, R.; Namba, N.; Cheong, H.I.; et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial. Lancet 2019, 393, 2416–2427.
  26. Richter, B.; Faul, C. FGF23 Actions on Target Tissues-With and Without Klotho. Front. Endocrinol. (Lausanne) 2018, 9, 189.
  27. Ito, N.; Prideaux, M.; Wijenayaka, A.R.; Yang, D.; Ormsby, R.T.; Bonewald, L.F.; Atkins, G.J. Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23. Calcif. Tissue Int. 2021, 109, 66–76.
  28. Courbebaisse, M.; Lanske, B. Biology of Fibroblast Growth Factor 23: From Physiology to Pathology. Cold Spring Harb. Perspect. Med. 2018, 8, a031260.
  29. Beck-Nielsen, S.S.; Mughal, Z.; Haffner, D.; Nilsson, O.; Levtchenko, E.; Ariceta, G.; de Lucas Collantes, C.; Schnabel, D.; Jandhyala, R.; Mäkitie, O. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis. 2019, 14, 58.
  30. Kurosu, H.; Ogawa, Y.; Miyoshi, M.; Yamamoto, M.; Nandi, A.; Rosenblatt, K.P.; Baum, M.G.; Schiavi, S.; Hu, M.-C.; Moe, O.W.; et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281, 6120–6123.
  31. Eswarakumar, V.P.; Lax, I.; Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16, 139–149.
  32. Ornitz, D.M.; Itoh, N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 2015, 4, 215–266.
  33. Belov, A.A.; Mohammadi, M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect. Biol. 2013, 5, a015958.
  34. Gattineni, J.; Bates, C.; Twombley, K.; Dwarakanath, V.; Robinson, M.L.; Goetz, R.; Mohammadi, M.; Baum, M. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Renal. Physiol. 2009, 297, F282–F291.
  35. Martin, A.; David, V.; Quarles, L.D. Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 2012, 92, 131–155.
  36. Fuente, R.; Gil-Peña, H.; Claramunt-Taberner, D.; Hernández, O.; Fernández-Iglesias, A.; Alonso-Durán, L.; Rodríguez-Rubio, E.; Santos, F. X-linked hypophosphatemia and growth. Rev. Endocr. Metab. Disord. 2017, 18, 107–115.
  37. Lang, F.; Leibrock, C.; Pandyra, A.A.; Stournaras, C.; Wagner, C.A.; Föller, M. Phosphate Homeostasis, Inflammation and the Regulation of FGF-23. Kidney Blood Press Res. 2018, 43, 1742–1748.
  38. Hu, M.C.; Shiizaki, K.; Kuro-o, M.; Moe, O.W. Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 2013, 75, 503–533.
  39. Shimada, T.; Urakawa, I.; Yamazaki, Y.; Hasegawa, H.; Hino, R.; Yoneya, T.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Yamashita, T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 2004, 314, 409–414.
  40. Shimada, T.; Hasegawa, H.; Yamazaki, Y.; Muto, T.; Hino, R.; Takeuchi, Y.; Fujita, T.; Nakahara, K.; Fukumoto, S.; Yamashita, T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19, 429–435.
  41. Quarles, L.D. Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease. Exp. Cell Res. 2012, 318, 1040–1048.
  42. Herrmann, M.; Engelke, K.; Ebert, R.; Müller-Deubert, S.; Rudert, M.; Ziouti, F.; Jundt, F.; Felsenberg, D.; Jakob, F. Interactions between Muscle and Bone-Where Physics Meets Biology. Biomolecules 2020, 10, 432.
  43. Veilleux, L.-N.; Rauch, F. Muscle-Bone Interactions in Pediatric Bone Diseases. Curr. Osteoporos. Rep. 2017, 15, 425–432.
  44. Glorieux, F.H.; Bonewald, L.F.; Harvey, N.C.; van der Meulen, M.C.H. Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet J. Rare Dis. 2022, 17, 30.
  45. Orlando, G.; Bubbear, J.; Clarke, S.; Keen, R.; Roy, M.; Anilkumar, A.; Schini, M.; Walsh, J.S.; Javaid, M.K.; Ireland, A. Physical function and physical activity in adults with X-linked hypophosphatemia. Osteoporos. Int. 2022, 33, 1485–1491.
  46. Skrinar, A.; Dvorak-Ewell, M.; Evins, A.; Macica, C.; Linglart, A.; Imel, E.A.; Theodore-Oklota, C.; San Martin, J. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey. J. Endocr. Soc. 2019, 3, 1321–1334.
  47. Ito, N. Adult Presentation of X-Linked Hypophosphatemia. Endocrines 2022, 3, 375–390.
  48. Mo, C.; Romero-Suarez, S.; Bonewald, L.; Johnson, M.; Brotto, M. Prostaglandin E2: From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. Recent Pat. Biotechnol. 2012, 6, 223–229.
  49. Bonewald, L.F. The Role of the Osteocyte in Bone and Nonbone Disease. Endocrinol. Metab. Clin. North Am. 2017, 46, 1–18.
  50. Veilleux, L.-N.; Cheung, M.; Ben Amor, M.; Rauch, F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2012, 97, E1492–E1498.
  51. Veilleux, L.-N.; Cheung, M.S.; Glorieux, F.H.; Rauch, F. The muscle-bone relationship in X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2013, 98, E990–E995.
  52. Farr, J.N.; Funk, J.L.; Chen, Z.; Lisse, J.R.; Blew, R.M.; Lee, V.R.; Laudermilk, M.; Lohman, T.G.; Going, S.B. Skeletal muscle fat content is inversely associated with bone strength in young girls. J. Bone Miner. Res. 2011, 26, 2217–2225.
  53. Goodpaster, B.H.; Kelley, D.E.; Thaete, F.L.; He, J.; Ross, R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J. Appl. Physiol. (1985) 2000, 89, 104–110.
  54. Mao, M.; Carpenter, T.O.; Whyte, M.P.; Skrinar, A.; Chen, C.-Y.; San Martin, J.; Rogol, A.D. Growth Curves for Children with X-linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 2020, 105, 3243–3249.
  55. Carpenter, T.O.; Whyte, M.P.; Imel, E.A.; Boot, A.M.; Högler, W.; Linglart, A.; Padidela, R.; Van’t Hoff, W.; Mao, M.; Chen, C.-Y.; et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N. Engl. J. Med. 2018, 378, 1987–1998.
  56. Whyte, M.P.; Carpenter, T.O.; Gottesman, G.S.; Mao, M.; Skrinar, A.; San Martin, J.; Imel, E.A. Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: A multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019, 7, 189–199.
  57. Kemp, G.J.; Meyerspeer, M.; Moser, E. Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: A quantitative review. NMR Biomed 2007, 20, 555–565.
  58. Kavanaugh, M.P.; Kabat, D. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int. 1996, 49, 959–963.
  59. Schneider, H.; Steenbock, H. A Low Phosphorus Diet and the Response of Rats to Vitamin D2. J. Biol. Chem. 1939, 128, 159–171.
  60. Knochel, J.P.; Barcenas, C.; Cotton, J.R.; Fuller, T.J.; Haller, R.; Carter, N.W. Hypophosphatemia and rhabdomyolysis. J. Clin. Invest. 1978, 62, 1240–1246.
  61. Soyoral, Y.; Aslan, M.; Ebinc, S.; Dirik, Y.; Demir, C. Life-threatening hypophosphatemia and/or phosphate depletion in a patient with acute lymphoblastic leukemia: A rare case report. Am. J. Emerg. Med. 2014, 32, 1437.e3–1437.e5.
  62. Geerse, D.A.; Bindels, A.J.; Kuiper, M.A.; Roos, A.N.; Spronk, P.E.; Schultz, M.J. Treatment of hypophosphatemia in the intensive care unit: A review. Crit. Care 2010, 14, R147.
  63. Lotz, M.; Zisman, E.; Bartter, F.C. Evidence for a phosphorus-depletion syndrome in man. N. Engl. J. Med. 1968, 278, 409–415.
  64. Raimann, A.; Dangl, A.; Javanmardi, A.; Greber-Platzer, S.; Egerbacher, M.; Pietschmann, P.; Haeusler, G. Elevation of phosphate levels impairs skeletal myoblast differentiation. Cell Tissue Res. 2020, 382, 427–432.
  65. Sosa, P.; Alcalde-Estévez, E.; Asenjo-Bueno, A.; Plaza, P.; Carrillo-López, N.; Olmos, G.; López-Ongil, S.; Ruiz-Torres, M.P. Aging-related hyperphosphatemia impairs myogenic differentiation and enhances fibrosis in skeletal muscle. J. Cachexia Sarcopenia Muscle 2021, 12, 1266–1279.
  66. Sosa, P.; Alcalde-Estevez, E.; Plaza, P.; Troyano, N.; Alonso, C.; Martínez-Arias, L.; Evelem de Melo Aroeira, A.; Rodriguez-Puyol, D.; Olmos, G.; López-Ongil, S.; et al. Hyperphosphatemia Promotes Senescence of Myoblasts by Impairing Autophagy Through Ilk Overexpression, A Possible Mechanism Involved in Sarcopenia. Aging Dis. 2018, 9, 769–784.
  67. Pesta, D.H.; Tsirigotis, D.N.; Befroy, D.E.; Caballero, D.; Jurczak, M.J.; Rahimi, Y.; Cline, G.W.; Dufour, S.; Birkenfeld, A.L.; Rothman, D.L.; et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB J. 2016, 30, 3378–3387.
  68. Fuller, T.J.; Carter, N.W.; Barcenas, C.; Knochel, J.P. Reversible changes of the muscle cell in experimental phosphorus deficiency. J. Clin. Invest. 1976, 57, 1019–1024.
  69. Effects of Phosphorus Deficiency on Theultrastructure of the Rat Fast Twitchskeletal Muscle | Semantic Scholar. Available online: https://www.semanticscholar.org/paper/Effects-of-phosphorus-deficiency-on-of-the-rat-fast-Finol-Venanzi/32b6deb0dcb895b0e76501acc56b34d3205292fd (accessed on 18 July 2022).
  70. Hoshino, C.; Satoh, N.; Sugawara, S.; Kuriyama, C.; Kikuchi, A.; Ohta, M. Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23. Intern. Med. 2008, 47, 453–457.
  71. Land, J.M.; Kemp, G.J.; Taylor, D.J.; Standing, S.J.; Radda, G.K.; Rajagopalan, B. Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia. Neuromuscul. Disord. 1993, 3, 223–225.
  72. Schubert, L.; DeLuca, H.F. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch. Biochem. Biophys. 2010, 500, 157–161.
  73. Claus, K.N.; Day, T.K.; Wolf, C. Neuromuscular signs associated with acute hypophosphatemia in a dog. J. Am. Anim. Hosp. Assoc. 2015, 51, 161–166.
  74. BARTALI, B.; SEMBA, R.D.; ARAUJO, A.B. KLOTHO, FGF21 AND FGF23: NOVEL PATHWAYS TO MUSCULOSKELETAL HEALTH? J. Frailty Aging 2013, 2, 179–183.
  75. Saito, T.; Fukumoto, S. Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. Int. J. Pediatr. Endocrinol. 2009, 2009, 496514.
  76. Ito, N.; Fukumoto, S.; Takeuchi, Y.; Takeda, S.; Suzuki, H.; Yamashita, T.; Fujita, T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J. Bone Miner. Metab. 2007, 25, 419–422.
  77. Hana, T.; Tanaka, S.; Nakatomi, H.; Shojima, M.; Fukumoto, S.; Ikemura, M.; Saito, N. Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23. Endocr. J. 2017, 64, 1033–1039.
  78. Yavropoulou, M.P.; Gerothanasi, N.; Frydas, A.; Triantafyllou, E.; Poulios, C.; Hytiroglou, P.; Apostolou, P.; Papasotiriou, I.; Tournis, S.; Kesisoglou, I.; et al. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol. Diabetes Metab. Case Rep. 2015, 2015, 150025.
  79. Minisola, S.; Peacock, M.; Fukumoto, S.; Cipriani, C.; Pepe, J.; Tella, S.H.; Collins, M.T. Tumour-induced osteomalacia. Nat. Rev. Dis. Primers 2017, 3, 17044.
  80. Aono, Y.; Hasegawa, H.; Yamazaki, Y.; Shimada, T.; Fujita, T.; Yamashita, T.; Fukumoto, S. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J. Bone Miner. Res. 2011, 26, 803–810.
  81. Fukasawa, H.; Ishigaki, S.; Kinoshita-Katahashi, N.; Niwa, H.; Yasuda, H.; Kumagai, H.; Furuya, R. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients. Nephrology (Carlton) 2014, 19, 784–790.
  82. Erben, R.G.; Mayer, D.; Weber, K.; Jonsson, K.; Jüppner, H.; Lanske, B. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J. Bone Miner. Res. 2005, 20, 1149–1160.
  83. Yablonka-Reuveni, Z.; Danoviz, M.E.; Phelps, M.; Stuelsatz, P. Myogenic-specific ablation of Fgfr1 impairs FGF2-mediated proliferation of satellite cells at the myofiber niche but does not abolish the capacity for muscle regeneration. Front. Aging Neurosci. 2015, 7, 85.
  84. Sato, C.; Iso, Y.; Mizukami, T.; Otabe, K.; Sasai, M.; Kurata, M.; Sanbe, T.; Sekiya, I.; Miyazaki, A.; Suzuki, H. Fibroblast growth factor-23 induces cellular senescence in human mesenchymal stem cells from skeletal muscle. Biochem. Biophys. Res. Commun. 2016, 470, 657–662.
  85. Avin, K.G.; Vallejo, J.A.; Chen, N.X.; Wang, K.; Touchberry, C.D.; Brotto, M.; Dallas, S.L.; Moe, S.M.; Wacker, M.J. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am. J. Physiol. Endocrinol. Metab. 2018, 315, E594–E604.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback